Skip to content
Citation only via OpenAlex

Klotho to Treat Kidney Fibrosis

María Dolores Sánchez-Niño, Ana Belen Sanz, Alberto Ortíz

Journal of the American Society of Nephrology · 2013 · ▲ 41 citations

Abstract

Sixteen years ago, defective expression of the murine klotho gene was found to result in a syndrome resembling human aging.1 Tubular kidney cells were the main sites of Klotho expression. Rescue of the phenotype by expression of a Klotho transgene outside the kidney suggested a humoral regulation of aging.1 These findings supported the concept of Klotho as a kidney-secreted hormone like erythropoietin. Klotho is now known to be both a membrane-bound and a secreted protein. A key function of Klotho is to regulate phosphate metabolism by both being a necessary coreceptor for the phosphaturic hormone fibroblast growth factor-23 and directly inhibiting tubular phosphate reabsorption by the sodium-phosphate cotransporter NaPi2a.2,3 In addition, a growing list of actions of soluble Klotho depend on its glycosidase activity or binding to cell membrane receptors and transporters and as reported by Zhou et al.,2,4 soluble ligands. Thus, Klotho regulates insulin/IGF-1, Wnt, and TGF-β1 signaling as well as renal outer medullary potassium channel (ROMK), transient receptor potential channel 5 (TRPC5), and TRPC6 availability.2 Loss of Klotho may contribute to the aging-like features of human CKD and progression of CKD.5–7 The initial description of the mouse Klotho gene reported normal serum creatinine in mutant mice.1 However, Klotho−/− mice develop renal failure characterized by kidney calcification and increased renal cell apoptosis, suggesting that Klotho deficiency is deleterious for the kidney.6 The loss of Klotho during kidney disease coupled with a negative impact of Klotho deficiency on kidney disease may potentially generate a vicious circle where kidney injury results in low kidney Klotho and Klotho downregulation favors progression of kidney injury. In the current issue of JASN, Zhou et al.4 now provide evidence supporting the existence of such a vicious circle leading to kidney fibrosis, characterized by the interplay of Klotho, TGF-β1, and Wnt/β-catenin signaling.4 Either preventing Klotho downregulation or supplementing the missing Klotho may interrupt the vicious circle.4 The observation that urinary Klotho is reduced already in stage I human CKD suggests that there are factors that reduce Klotho synthesis by tubular epithelium beyond the loss of Klotho-producing cells.5 TNF superfamily inflammatory cytokines, TGF-β1 or angiotensin II, decrease Klotho expression in cultured tubular cells.2,3,7,8 Zhou et al.4 confirm a TNF-independent Klotho-lowering effect of TGF-β1 in cultured renal cells. Zhou et al.4 propose that TGF-β1 could be the culprit behind Klotho depletion in diseased kidneys. However, key experiments were missing to fully support this notion. Thus, the effect of systemic TGF-β1 administration or neutralization on kidney Klotho expression was not studied. In this regard, systemic delivery of TWEAK (TNF-like weak inducer of apoptosis) or angiotensin II decreases levels of kidney Klotho, and targeting of TWEAK, TNF, or the renin-angiotensin system prevents kidney Klotho downregulation in animal models of kidney injury or systemic inflammation.3,8,9 Similar functional studies should define the relative in vivo contribution of TGF-β1 to the regulation of kidney Klotho levels. Currently available data support a model where multiple tubular cell stressors decrease Klotho synthesis. Thus, constitutive transcription of Klotho in tubular epithelial cells is downregulated by transcription factors (NF-κB or Smad-3) or epigenetic modulation and rapidly results in decreased protein levels.4,8 Animal models of AKI and CKD have uniformly shown decreased kidney Klotho as well as a nephroprotective role of Klotho.2–5,7,8,10,11 Klotho sits at the AKI to CKD interface. Kidney Klotho is decreased early in the course of experimental AKI and persists decreased well beyond the recovery of normal renal function,8 which was reproduced by Zhou et al.4 In addition, kidney Klotho is decreased in experimental CKD of ischemic, unilateral ureteral obstruction (UUO), or glomerular origin.4,11 Zhou et al.4 now add to the literature on the role of Klotho in CKD and kidney fibrosis resulting from these causes.4,5,7,10,11 Klotho deficiency aggravates fibrosis resulting from UUO.7 Klotho overexpression in ICR-derived GN mice leads to improved renal function and decreased apoptosis and fibrosis both in the tubular and glomerular compartments.11 In a model of angiotensin II administration, an adenovirus harboring the mouse klotho gene improves creatinine clearance and a tubulointerstitial injury score that includes thickening of the tubular basement membrane.12 Administration of secreted Klotho to mice immediately after the procedure suppressed renal fibrosis induced by UUO.10 Genetic low Klotho levels impair renal function and proteinuria, and high Klotho expression protects from both in CKD induced by ischemia reperfusion in a solitary kidney.5 Where is the novelty of the current report? Zhou et al.,4 for the first time, show that overexpression of exogenous Klotho at late time points, when kidney lesions are already established, is still therapeutically effective to prevent fibrosis.4 This finding is a significant advance, because clinic diagnosis is frequently delayed, and therapy is applied when some degree of kidney injury has already occurred and not prophylactically. Thus, this clear step is in the direction of clinical studies on Klotho therapy for CKD. Kidney protection by Klotho overexpression extends beyond the tubulointerstitium and into the glomerulus in adriamycin nephropathy, tending to reduce proteinuria and preserving nephrin expression.4 Whether Klotho might even restore nephrin expression should be further studied. Glomerular protection is in accordance to observations of Klotho reducing glomerulosclerosis in ICR-derived GN mice and reducing proteinuria in ischemia reperfusion-induced CKD.5,11 This finding suggests podocyte actions of Klotho. Indeed, in addition to protecting from angiotensin

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1681/asn.2013030294
Canonical
link ↗
Fetched
2026-10-26 MST

Cite this

APA
Sánchez-Niño, M.D., Sanz, A.B., &amp; Ortíz, A. (2013). Klotho to Treat Kidney Fibrosis. <em>Journal of the American Society of Nephrology</em>. https://doi.org/10.1681/asn.2013030294
Vancouver
Sánchez-Niño MD, Sanz AB, Ortíz A. Klotho to Treat Kidney Fibrosis. Journal of the American Society of Nephrology. 2013. doi:10.1681/asn.2013030294.
BibTeX
@article{mara2013Klotho, title = {Klotho to Treat Kidney Fibrosis}, author = {María Dolores Sánchez-Niño and Ana Belen Sanz and Alberto Ortíz}, journal = {Journal of the American Society of Nephrology}, year = {2013}, doi = {10.1681/asn.2013030294}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings